Hear insights from Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD, on some of the most important new data reported at the 4th HIV Research for Prevention Conference (HIVR4P // Virtual), including results from studies evaluating novel approaches to HIV prevention such as broadly neutralizing antibodies, long-acting injectable and oral ARVs, implantable options, multipurpose prevention strategies, and key aspects of PrEP implementation.
In this episode, Dr. Bekker discusses results from key studies reported at the 4th HIV Research for Prevention Conference (HIVR4P // Virtual), including results from studies evaluating novel approaches to HIV prevention such as broadly neutralizing antibodies, long-acting injectable and oral ARVs, and implantable options. In addition, Dr. Bekker will discuss several studies evaluating different aspects of PrEP implementation and acceptance as well as considerations for multipurpose prevention strategies.
Presenter:
Linda-Gail Bekker, MBChB, DTM&H, DCH, FCP(SA), PhD
Director
Desmond Tutu HIV Centre
Past President
International AIDS Society
Faculty of Health Sciences
University of Cape Town
Cape Town, South Africa
Content based on a CME program supported by independent educational grants from Gilead Sciences, Inc.; Janssen Therapeutics, Division of Janssen Products, LP; Merck Sharp & Dohme Corp; and ViiV Healthcare.
Link to full program:
http://bit.ly/3s41GtM